Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, Heinrich MC, Tyner JW, Rea D, Cayuela JM, Kim DW, Tognon CE, O'Hare T, Druker BJ, Deininger MW. Eide CA, et al. Among authors: than h. Cancer Cell. 2019 Oct 14;36(4):431-443.e5. doi: 10.1016/j.ccell.2019.08.004. Epub 2019 Sep 19. Cancer Cell. 2019. PMID: 31543464 Free PMC article.
SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Sinnakannu JR, Lee KL, Cheng S, Li J, Yu M, Tan SP, Ong CCH, Li H, Than H, Anczuków-Camarda O, Krainer AR, Roca X, Rozen SG, Iqbal J, Yang H, Chuah C, Ong ST. Sinnakannu JR, et al. Among authors: than h. Leukemia. 2020 Jul;34(7):1787-1798. doi: 10.1038/s41375-020-0732-1. Epub 2020 Feb 12. Leukemia. 2020. PMID: 32051529 Free PMC article.
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, Chan ZE, Yu M, Makheja M, Rayan NA, Lim MGL, Cheung AMS, Bari S, Chng WJ, Than H, Ouyang J, Rackham O, Tan TZ, Hwang WYK, Chuah C, Prabhakar S, Ong ST. Krishnan V, et al. Among authors: than h. Blood. 2023 Jun 1;141(22):2738-2755. doi: 10.1182/blood.2022017295. Blood. 2023. PMID: 36857629 Free article.
Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore.
Tan JY, Ling VWT, Ng LCK, Krisnadi C, Tan MSY, Grigoropoulos NF, Ong SY, Nagarajan C, Quek JKS, Than H, Lee J, Chan E, Tan LK, Hwang WYK, Goh YT, Linn YC, Koh LP, Ho AYL, Lim FWI, Poon ML, Chen Y. Tan JY, et al. Among authors: than h. Hematol Oncol. 2025 Jan;43(1):e70030. doi: 10.1002/hon.70030. Hematol Oncol. 2025. PMID: 39729576 No abstract available.
Fusion Genes in Myeloid Malignancies.
Ang CH, Than H, Tuy TT, Goh YT. Ang CH, et al. Among authors: than h. Cancers (Basel). 2024 Dec 3;16(23):4055. doi: 10.3390/cancers16234055. Cancers (Basel). 2024. PMID: 39682241 Free PMC article. Review.
Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton WL, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Prchal JT, O'Hare T, Deininger MW. Yan D, et al. Among authors: than h. Clin Cancer Res. 2019 Apr 1;25(7):2323-2335. doi: 10.1158/1078-0432.CCR-18-0959. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563936 Free PMC article.
49 results